Vera Therapeutics, Inc. (VERA) Investor Relations Documents

Vera Therapeutics, Inc. (VERA) investor relations documents from the company's IR site: 3 presentations, 15 press releases; latest deck 2026-08-14. Read in-app with summaries. First-party data.

Corporate Presentation: Vera Therapeutics' TRUTAKNA (atacicept-vymj) received FDA accelerated approval for IgAN, with Phase 3 eGFR results expected Q3 2026. The company has ~$499M cash.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-14PresentationCorporate Presentation
2026-08-10Press releaseVera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
2026-08-07Press releaseVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-10Press releaseVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-09Press releaseVera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Tur
2026-07-07Press releaseVera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
2026-06-05PresentationFocused Oral Presentations: ORIGIN 3 Subgroup Analysis, PIONEER IgAN Preliminary Findings, and ORIGIN Extend Off-Treatme
2026-06-05Press releaseVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-02Press releaseVera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
2026-05-08Press releaseVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-07Press releaseVera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
2026-04-10Press releaseVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-03-27Press releaseVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseVera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
2026-02-24Press releaseVera Therapeutics to Participate at Upcoming Investor Conferences
2026-01-08Press releaseVera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
2026-01-07Press releaseVera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatmen
2025-11-06PresentationORIGIN Phase 3 Update

VERA overview · VERA earnings · VERA financials · VERA KPIs · VERA documents · VERA ownership · VERA peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.